United Kingdom
Re-Vana Therapeutics, founded in 2016 and headquartered in the United Kingdom, is committed to improving patient care for sight-threatening diseases through innovative drug delivery systems. The company operates within the Health Care and Health and Wellness sectors.
Its pioneering approach addresses the significant unmet need in intravitreal anti-VEGF therapies, which are projected to reach $19 billion by 2029. Traditional methods require frequent injections due to rapid drug clearance, often leading to suboptimal patient outcomes. Re-Vana offers a novel solution with photo crosslinked biodegradable hydrogel technologies like EyeLief®, EyeLief-SD™, and OcuLief®, enabling sustained drug release and reducing treatment frequency to potentially once a year.
The company secured a £10.00M Series A investment in November 2022, with backing from notable investors, including Techstart Ventures, ExSight Ventures, and Visionary Ventures. A strategic collaboration with Boehringer Ingelheim was announced in July 2025, propelling the development of long-acting therapies. This positions Re-Vana as a promising player addressing an enormous market opportunity.
